NCT00100932View on ClinicalTrials.gov

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

PHASE2CompletedINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

June 30, 2008

Conditions

Non-Small-Cell Lung Carcinoma

Interventions

DRUG

E7389 28 Day Cycle

E7389 1.4 mg/m\^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.

DRUG

E7389 21 Day Cycle

E7389 1.4 mg/m\^2 IV bolus on Days 1 and 8 of a 21 day cycle.

Trial Locations (13)

Unknown

Gilroy

Ocala

Baltimore

Columbia

Saint Joseph

St Louis

McCook

Canton

Dallas

Fort Worth

Fairfax

Norfolk

Vancouver

All Listed Sponsors

lead

Eisai Inc.

INDUSTRY

NCT00100932 - Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy | Biotech Hunter | Biotech Hunter